- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04248556
Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization
Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization Under Controlled and Maximised Conditions
This is a clinical study for health care product safety assessment. The research will be conducted with 92 subjects, aged 18 to 59 years. The product will be applied on the right and/or left back of the research participants for 3 consecutive weeks. After 10 days, will have another application of the same product, which will be removed in 48 hours. Medical evaluation will be available throughout the study to assess possible adverse events.
The objective of the study is to observe the effects of the application of the product on the skin and prove the absence of irritability and/or allergy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13084-791
- Allergisa Pesquisa Dermato-Cosmetica Ltda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Agreement to comply with safety guidelines to minimize contamination risks to COVID-19;
- Agreement to perform a molecular test to detect COVID-19 to enter the study;
- Healthy participants;
- Non-injured skin in the test region;
- Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations;
- ability to consent to participation in the study;
- Age from 18 to 59 years;
- Phototype (Fitzpatrick): I to IV;
- All sex.
Exclusion Criteria:
- Participants who belong to the risk group for COVID-19, that is, with diabetes, with chronic cardiovascular, renal and respiratory problems, immunosuppressed or other conditions that the doctor deems to belong to the risk group;
- Pregnant or breastfeeding women;
- Skin marks in the experimental area that interfere with the evaluation of possible skin reactions;
- Active dermatoses;
- Background of allergic reactions, irritation or intense discomfort sensations to topical use products;
- History of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.);
- Sensation of discomfort with temperature changes (too hot/very cold) and/or when in the air conditioning;
- Participants with a history of allergy to materials used in the study;
- History of pathologies aggravated or triggered by ultraviolet radiation;
- Carriers of immunodeficiencies;
- Intense sun exposure or tanning session up to 15 days before the initial evaluation;
- Prediction of intense sun exposure or tanning session during the course of the study;
- Expected to bathe in the sea, pool or bathtub during the conduct of the study;
- Participants who practice water sports;
- Dermography;
- Aesthetic and/or body dermatological treatment until 03 weeks before the selection;
- Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids until 2 weeks before selection or, considering deposit corticoids, the interval shall be 1 month before selection;
- Treatment with acidic vitamin A and/or its derivatives via oral or topical up to 1 month before the start of the study;
- Vaccination during the study or up to 3 weeks before the study;
- Being or having participated in another clinical trial terminated less than 7 days before selection, if the previous trial is acceptable in use;
- Being or having participated in another clinical trial terminated less than 21 days before the selection, in case the previous trial is compatible or Adverse Reaction investigative;
- Any condition not mentioned above that, in the opinion of the investigator, may compromise the assessment of the trial;
- History of no adherence or unwillingness to adhere to the study protocol;
- Professionals directly involved in the conduct of this protocol and their families.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: subjects, 18-59 y, healthy
patch test with investigation product
|
Health care product (gel) - to be applied on the participant's skin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence
Time Frame: 4 weeks
|
Absence of the occurrence of reactions of primary, accumulated dermal irritation and of allergic reactions by sensitization by the investigational products.
|
4 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- All-S-RIPT-SO-PAD-074832
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sensitivity, Contact
-
Herbarium Laboratorio Botanico LtdaCompletedSensitivity, ContactBrazil
-
UNION therapeuticsCompleted
-
Herbarium Laboratorio Botanico LtdaCompletedAcceptance, Social | Sensitivity, ContactBrazil
-
Herbarium Laboratorio Botanico LtdaCompleted
-
Herbarium Laboratorio Botanico LtdaCompleted
-
Navamindradhiraj UniversityActive, not recruiting
-
EV Clinical TrialsCompletedContact Lens Discomfort | Contact Lens | Contact Lens DrynessUnited States
-
Hospices Civils de LyonRecruitingContact Dermatitis | Contact Dermatitis Irritant | Contact Dermatitis, AllergicFrance
-
Ramsay Générale de SantéInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingEczema | Allergic Contact Eczema NosFrance, Belgium
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
Clinical Trials on Health care product
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Diseases | Atrophic VaginitisBrazil
-
Karolinska InstitutetNot yet recruitingPhysical Activity | COPD | Implementation
-
LifeNet HealthCompletedDiabetic Foot UlcerUnited States
-
Herbarium Laboratorio Botanico LtdaCompleted
-
Radicle ScienceCompletedDepression | Pain | Sleep | AnxietyUnited States
-
Capital Health, CanadaSunnybrook Health Sciences Centre; Erasmus Medical Center; IWK Health Centre; Afexa... and other collaboratorsCompletedRespiratory Tract InfectionCanada, Netherlands
-
Radicle ScienceActive, not recruitingAbdominal Pain | Digestion | GI DisordersUnited States
-
Boston Children's HospitalSouth Shore HospitalCompletedAsthma | Urinary Tract Infection | Otitis Media | Head InjuryUnited States
-
Yonsei UniversityCompletedPancreaticobiliary CancerKorea, Republic of
-
Delivra, Inc.Completed